

Cohesin and Cohesin Related Proteins: A New Frontier for Alzheimer Disease Exploration

Vladan P Bajic^{1*} and Biljana Spremo- Potparevic²

¹*The Laboratory for Radiobiology and Molecular Genetics, Institute for Nuclear Research "Vinča", University of Belgrade, Belgrade, Serbia*

²*Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia*

***Corresponding Author:** Bajic P Vladan, Research Professor, Department of Radiobiology and Molecular Genetics, Institute for Nuclear Research "Vinca", University of Belgrade, Belgrade, Serbia.

Received: January 10, 2019; **Published:** February 21, 2019

Recently, Rao CV, *et al.* [1] produced a mice model of Late onset Alzheimer's disease (LOAD) in which a protein, Shugoshin 1 ("guardian spirit" in Japanese), that is known for its binding properties to chromatids by protecting [2] a central protein, cohesin is altered leading to cognitive changes and neurodegeneration [3].

Using this model the authors showed for the first time that Alzheimer type dementia can be produced when the mice hit a certain age, suggesting that this model can reflect LOAD.

Shugoshin 1 is fundamental to the cohesion process and to the cell cycle [4,5] and dependently works with the central core cohesion protein, Cohesin [6].

Cohesin is a complex protein that is organized through its subunits, SMC1 and 3, (SA1) Rad 21 and SA2 [7,8]. A number of cohesin related proteins have been elucidated in the processes of cell mitosis and the regulation neuronal development, migration and maturation [9]. These late phase cell cycle proteins that regulate the cohesion process by addressing the cohesion protein, cohesin, have been heavily reviewed [10-12].

In 2004, a group led by Prof Biljana Spremo Potparevic [13] found that the cohesion process is altered in peripheral blood lymphocytes in AD patients. The alteration coined by Vig, *et al.* [14] as premature centromere division showed that the X chromosome is especially susceptible to cohesin degradation before its time. Phenotypically, chromatids appear to have no cohesion between their chromatids [15,16]. This work was extended to neurons. We found that neurons of women are indeed more prone to PCD than men. These results were published in Neurochemistry in 2008 [17].

In 2007 the cohesion theory was recognized by my dear friend and colleague, Prof. Dr Mark A Smith *(more than 15.000 citations and 800 papers) and I was able to come to his laboratory as a Fulbright scholar.

The question that we put at hand is how cohesion and, or cohesion related proteins that phenotypically express PCD are altered in AD? As I have elaborated previous literature about how cohesion-cohesin is altered in different syndromes and cancer models and disease that express PCD [10-15], I have chosen and was given three antibodies to work with, Rad 21, CDK 11 and Rad 51.

Our work was published for cohesion related mechanisms and CDK 11 in normal and AD subjects in 2008, 2009 and 2011 [18-20]. CDK 11 shows differential expression in AD versus age matched controls. Rakkaa, *et al.* [21] showed that shugoshin 1 and Bub1 where not present at the centromeres if CDK1158 was depleted.

Results for Rad 21 haven't been published yet. Preliminary research showed that Rad 21 (a cohesion subunit) is decreased in Abeta neuroblastoma transfected cells [22]. Rad 51, a protein important in DNA repair showed inconclusive evidence. The rationale for its use was that RAD 51 is a hub protein in survival vs apoptotic processes in cells/bacteria exposed to xenobiotics [23].

We believe that the neuronal regulation of last phase cell cycle proteins are the cap stone to the cell cycle re-entry hypothesis. For that, in 2016 we published a paper in which we suggest that late phase cell cycle proteins have a value to be explored as potential drugs for AD treatment [24].

Beforehand, as a DAAD fellow in 2011. I was introduced to Prof Thomas Arendt's Lab in Leipzig, Germany. We explored a number of cohesin related proteins, MAD2, MAD 2b, Bub R1, Bub 1. All of these proteins in our preliminary research show altered expression in AD brain tissue using immunohistochemistry and Western blot methods. Results were reported on a number of Congresses [25,26].

Our work, with the work of Prof Dr Biljana Spremo Potparevic have been published as the cohesion-aneuploidy hypothesis of AD [27].

Interestingly enough, late phase cell cycle proteins have been found to be deregulated not only in AD [27], neuro-development syndromes (Roberts syndrome, Corney de Lang) [28,29] but also in diabetes [30,31] suggesting a connection between these disease and secondary roles of cohesin and cohesin related proteins [9,24,27,32].

The new frontier to AD research is opened as the new mouse model may give us new insights of how all these proteins are regulated in normal versus affected neurons, suggesting how age and environment influences the effect on the neurodegenerative process. These new insights may lead us to new avenues for treatment and cure of Alzheimer's disease.

Acknowledgments

This research was supported by the Ministry of Education, Science and Technological Development of Serbia (Grant OI173034), Fulbright Scholar Program and German DAAD Program.

Bibliography

1. Rao CV, *et al.* "Spontaneous development of Alzheimer's disease-associated brain pathology in a Shugoshin-1 mouse cohesinopathy model". *Aging Cell* 25 (2018): e12797.
2. Watanabe Y and Kitajima TS. "Shugoshin protects cohesin complexes at centromeres". *Philosophical Transactions of the Royal Society of London. Series B Biological Sciences* 360.1455 (2005): 515-512.
3. Rao CV, *et al.* "Critical role of mitosis in spontaneous late-onset alzheimer's disease from a Shugoshin 1 cohesinopathy mouse model". *Cell Cycle* 17.19-20 (2018): 2321-2334.
4. Lang F, *et al.* "Shugoshin1 is dislocated by KSHV-encoded LANA inducing aneuploidy". *PLoS Pathogen* 14.9 (2018): e1007253.
5. Murakami-Tonami, *et al.* "SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells". *Scientific Reports* 6 (2016): 31615.
6. Onn I, *et al.* "Sister chromatid cohesion: a simple concept with a complex reality". *Annual Review of Cell and Developmental Biology* 24 (2008): 105-129.
7. Ström L and Sjögren C. "DNA damage-induced cohesion". *Cell Cycle* 4.4 (2005): 536-539.
8. Suja JA and Barbero JL. "Cohesin complexes and sister chromatid cohesion in mammalian meiosis". *Genome Dynamics* 5 (2009): 94-116.
9. Frank CL and Tsai LH. "Alternative Functions of Core Cell Cycle Regulators in Neuronal Migration, Neuronal Maturation, and Synaptic Plasticity". *Neuron* 62.3 (2009): 312-326.

10. Nasmyth K. "How do so few control so many?" *Cell* 120.6 (2005): 739-746.
11. Nasmyth K and Haering CH. "The structure and function of SMC and kleisin complexes". *Annual Review of Biochemistry* 74 (2005): 595-648.
12. Srinivasan M., *et al.* "The Cohesin Ring Uses Its Hinge to Organize DNA Using Non-topological as well as Topological Mechanisms". *Cell* 173.6 (2018): 1508-1519.e18.
13. Spremo-Potparevic B., *et al.* "Analysis of premature centromere division (PCD) of the X chromosome in Alzheimer patients through the cell cycle". *Experimental Gerontology* 39.5 (2004): 849-548.
14. Vig BK. "Sequence of centromere separation: role of centromeric heterochromatin". *Genetics* 102.4 (1982): 795-806.
15. Fitzgerald PH., *et al.* "Evidence for the repeated primary non-disjunction of chromosome 21 as a result of premature centromere division (PCD)". *Human Genetics* 72.1 (1986): 58-62.
16. Lagirand-Cantaloube J., *et al.* "Loss of Centromere Cohesion in Aneuploid Human Oocytes Correlates with Decreased Kinetochores Localization of the Sac Proteins Bub1 and BubR1". *Scientific Report* 7 (2017): 44001.
17. Spremo-Potparević B., *et al.* "Premature centromere division of the X chromosome in neurons in Alzheimer's disease". *Journal of Neurochemistry* 106.5 (2008): 2218-2223.
18. Bajić VP, *et al.* "Is the time dimension of the cell cycle re-entry in AD regulated by centromere cohesion dynamics?" *Bioscience Hypotheses* 1.3 (2008): 156-161.
19. Bajić VP, *et al.* "The X-chromosome instability phenotype in Alzheimer's disease: a clinical sign of accelerating aging?" *Medical Hypotheses* 73.6 (2009): 917-920.
20. Bajić VP, *et al.* "Mislocalization of CDK11/PITSLRE, a regulator of the G2/M phase of the cell cycle, in Alzheimer disease". *Cellular and Molecular Biology Letters* 16.3 (2011): 359-372.
21. Tarik Rakkaa., *et al.* "CDK11p58 kinase activity is required to protect sister chromatid cohesion at centromeres in mitosis". *Chromosome Research* 22.3 (2014): 267-276.
22. Bajic VP *et al.* "RAD 21 cohesion protein shows altered levels of expression in Swedish mutant phenotype of M17 neuroblastoma cells". *Alzheimer's and Dementia: The Journal of the Alzheimer's Association* 6.4 (2010): S257.
23. Bajic VP, *et al.* "Apoptotic versus genotoxic potential of antitumor agents: a Concept of duality in Unity". *Medical Hypothesis* 61.5-6 (2003): 131-138.
24. Bajic VP, *et al.* "Late Phase Cell cycle proteins in Alzheimer's Disease: a possible target for therapy?" *Journal of Systems and Integrative Neuroscience* 3.1 (2016): 1-8.
25. Bajic VP, *et al.* "Cell cycle protein mad2b shows differential expression in the ad brain: a case of multifunctionality?" 8th FENS Forum of Neuroscience (2012).
26. Bajic VP, *et al.* "Proteotoxic control in Alzheimer's Disease may be attained by BubR1: a possible target for therapy?" *The Journal of Prevention of Alzheimer's Disease* 2.4 (2015).
27. Bajic VP, *et al.* "Cohesion and the aneuploid phenotype in Alzheimer's disease: A tale of genome instability". *Neuroscience and Biobehavioral Reviews* 55 (2015): 365-374.
28. Vega H., *et al.* "Roberts syndromes caused by mutations in ESCO2, a human homolog of yeast ECO1 that is essential for the establishment of sister chromatid cohesion". *Nature Genetics* 37.5 (2005): 468-470.

29. Liu J and Krantz ID. "Cornelia de Lange syndrome, cohesin, and beyond". *Clinical Genetics* 76.4 (2009): 303-314.
30. Meng X., *et al.* "Protection of neurons from high glucose-induced injury by deletion of MAD2B". *Journal of Cellular and Molecular Medicine* 18.5 (2014): 844-851.
31. Meng X., *et al.* "Metformin Protects Neurons against Oxygen-Glucose Deprivation/Reoxygenation-Induced Injury by Down-Regulating MAD2B". *Cellular Physiology and Biochemistry* 40.3-4 (2016): 477-485.
32. Tang Z., *et al.* "Human Bub1 protects centromeric sister-chromatid cohesion through Shugoshin during mitosis". *Proceedings of the National Academy of Sciences of the United States of America* 101.52 (2004): 18012-18017.

Volume 11 Issue 3 March 2019

©All rights reserved by Vladan P Bajic and Biljana Spremo- Potparevic.